{"entity":{"id":"on-target-drug-validation","kind":"term","name":"On-target validation of drug effects","aka":["on-target versus off-target drug effects","genetic validation of drug mechanism"],"tldr":"A drug can change cell behavior through a different target from the one proposed. Complementary experiments help establish which mechanism actually caused the effect.","summary":"Primary genetic interrogation of selected cancer drugs found examples in which cell-killing activity persisted after loss of the proposed target. The study illustrates why pharmacological response alone is insufficient to establish a cancer dependency. Genetic perturbation, complementary compounds, suitable controls and target-engagement measurements address different parts of the claim. Agreement strengthens a mechanism within the tested system; it does not establish a safe or effective treatment in people.","asOf":"2026-11-11","links":[{"label":"Genetic validation of proposed cancer-drug targets (2019)","url":"https://doi.org/10.1126/scitranslmed.aaw8412"},{"label":"Workman and Collins, fit-for-purpose chemical probes (2010)","url":"https://pubmed.ncbi.nlm.nih.gov/20609406/"},{"label":"Arrowsmith et al., chemical-probe quality and controls (2015)","url":"https://pubmed.ncbi.nlm.nih.gov/26196764/"},{"label":"Sakai et al., BRCA2 restoration and acquired resistance (2009)","url":"https://pubmed.ncbi.nlm.nih.gov/19654294/"}],"tags":[],"related":["drug-target-engagement","crispr-copy-number-artifact","functional-variant-evidence"],"cancers":[],"sections":[],"technologies":["crispr-screens"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Controls and their limits. In chemical-probe practice an inactive close analogue serves as a negative control and a second, structurally unrelated probe reduces the chance of shared off-targets (Arrowsmith et al. 2015). Genetic perturbation is a separate line of evidence, with its own limit: removing a whole protein can differ from inhibiting one of its functions (the teaching lesson's reasoning, not a result read). The nearest real example is natural reversion: ovarian cancer lines from one BRCA2 mutation carrier acquired a secondary BRCA2 mutation that restored BRCA2 and went with resistance to cisplatin and a PARP inhibitor, and transient siRNA depletion of BRCA2 re-sensitised the restored clones (Sakai et al. 2009); that is natural reversion plus knockdown in one patient's lineage, and depletion is not pharmacological inhibition. Agreement among controls supports a mechanism in the tested system only.","What to do next with a viability result. If a compound lowers viability in culture at one concentration, measure engagement and relevant selectivity, compare an inactive analogue and an independent probe, and use a suitable genetic perturbation or rescue; exposure, product quality, safety and clinical evidence remain separate questions that controls do not settle."],"category":"Methods and models"},"route":"/terms/on-target-drug-validation/","neighbours":{"term":[{"id":"crispr-copy-number-artifact","kind":"term","name":"Copy-number artifacts in gene-dependency screens","route":"/terms/crispr-copy-number-artifact/"},{"id":"drug-target-engagement","kind":"term","name":"Drug target engagement","route":"/terms/drug-target-engagement/"},{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","route":"/terms/measurement-to-benefit-evidence/"},{"id":"functional-variant-evidence","kind":"term","name":"Functional evidence for a sequence variant","route":"/terms/functional-variant-evidence/"}],"technology":[{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/"}]}}